News Releases

Year

Sep 23, 2021

UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 23, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Cantor Fitzgerald 2021 Virtual

Sep 13, 2021

UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting

Final data from Phase 2b OPTIMA II trial of UGN-102 showed complete and durable response for intravesical instillation in patients with low-grade intermediate risk NMIBC Long-term data from pivotal OLYMPUS trial underscores durable benefit of Jelmyto ® for adult patients with low-grade upper tract

Sep 10, 2021

UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 10, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C.

Sep 03, 2021

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 3, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to

Aug 04, 2021

UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Strong Jelmyto® net product revenue of $13.0 million for the second quarter of 2021, representing more than 70% growth over the first quarter of 2021 Nearly 100 global centers activated for Phase 3 landmark ATLAS trial with lead pipeline candidate, UGN-102 Commenced Jelmyto geographic expansion

Jul 28, 2021

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel

Jelmyto ® granted expedited review in Israel Jelmyto is the only US FDA approved treatment for low-grade upper tract urothelial cancer PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 28, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel

Jul 28, 2021

UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021

Conference Call and Webcast Scheduled for Wednesday, August 4, 2021 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 28, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic

Jul 14, 2021

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

73% growth in net product revenue over 1Q 2021 to approximately $13.0 million in 2Q 2021 2Q 2021 operating expenses anticipated in the range of $33 to $38 million Full 2Q 2021 financial results and conference call to be reported on Wednesday, August 4, 2021 PRINCETON, N.J. --(BUSINESS WIRE)--Jul.

Jul 07, 2021

UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference

PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 7, 2021-- UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Ladenburg Thalmann Healthcare

Jun 04, 2021

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 4, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units (“RSUs”) to

Current page 1
Page 2
Page 3
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on